#Capricor Therapeutics Advances Duchenne Muscular Dystrophy Program With Positive FDA Inspection Outcome

Capricor gets Form 483 from FDA; WuXi Biologics' new China factory

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Capricor Therapeutics has received a Form 483 from the FDA after an inspection of its factory ...

#Capricor Therapeutics Advances Duchenne Muscular Dystrophy Program With Positive FDA Inspection Outcome

Capricor Therapeutics, a biotechnology company focused on developing innovative cell and exosome-based therapeutics for rare diseases, has announced significant regulatory progress for its Duchenne Muscular Dystrophy (DMD) program. The company reported the successful completion of a Pre-License Inspection (PLI) of its manufacturing facility located in San Diego by the U.S. Food and Drug Administration (FDA) for its lead therapeutic candidate, De…